Daniel Einhorn
Overview
Explore the profile of Daniel Einhorn including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
58
Citations
4163
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
DeFronzo R, Auchus R, Bancos I, Blonde L, Busch R, Buse J, et al.
BMJ Open
. 2024 Jul;
14(7):e081121.
PMID: 39013654
Introduction: Even with recent treatment advances, type 2 diabetes (T2D) remains poorly controlled for many patients, despite the best efforts to adhere to therapies and lifestyle modifications. Although estimates vary,...
2.
Blonde L, Umpierrez G, Reddy S, McGill J, Berga S, Bush M, et al.
Endocr Pract
. 2022 Aug;
28(10):923-1049.
PMID: 35963508
Objective: The objective of this clinical practice guideline is to provide updated and new evidence-based recommendations for the comprehensive care of persons with diabetes mellitus to clinicians, diabetes-care teams, other...
3.
Handelsman Y, Anderson J, Bakris G, Ballantyne C, Beckman J, Bhatt D, et al.
J Diabetes Complications
. 2021 Dec;
36(2):108101.
PMID: 34922811
Type 2 diabetes (T2D), chronic kidney disease (CKD), atherosclerotic cardiovascular disease (ASCVD), and heart failure (HF)-along with their associated risk factors-have overlapping etiologies, and two or more of these conditions...
4.
5.
Handelsman Y, Jellinger P, Guerin C, Bloomgarden Z, Brinton E, Budoff M, et al.
Endocr Pract
. 2021 Jan;
26(10):1196-1224.
PMID: 33471721
The treatment of lipid disorders begins with lifestyle therapy to improve nutrition, physical activity, weight, and other factors that affect lipids. Secondary causes of lipid disorders should be addressed, and...
6.
Umpierrez G, Holt E, Einhorn D, McGill J
Endocr Pract
. 2020 Apr;
26(Suppl 3):1-12.
PMID: 32339033
Improved glycemic control is associated with a reduced risk of diabetic complications. Optimal management of patients with type 2 diabetes includes nutritional therapy, physical activity, and pharmacotherapy for glycemic control....
7.
Garber A, Handelsman Y, Grunberger G, Einhorn D, Abrahamson M, Barzilay J, et al.
Endocr Pract
. 2020 Feb;
26(1):107-139.
PMID: 32022600
No abstract available.
8.
9.
Mende C, Einhorn D
Endocr Pract
. 2019 Apr;
25(8):854-858.
PMID: 31013163
To determine whether fatty kidney disease deserves be designated as a distinct clinical entity similar to fatty liver disease. Analysis and interpretation of the literature in a novel conceptual framework....
10.
Garber A, Abrahamson M, Barzilay J, Blonde L, Bloomgarden Z, Bush M, et al.
Endocr Pract
. 2019 Feb;
25(1):69-100.
PMID: 30742570
No abstract available.